The Transformative Potential of Gene Therapies
Monday September 12, 12:00 PM
(Lunch at 11:30 AM) In Person-VA Bio+Tech Park, Founder’s Room & Virtual- Zoom
COVID-19 has changed the world in many ways. As we continue to emerge from the pandemic, innovative companies are resuming work on novel cell and gene therapies. These ground-breaking, personalized tools are addressing illnesses that previously lacked sufficient solutions.
This briefing will explain the science behind cell and gene therapies, their incredible potential for positively impacting patients’ lives, and review the policy considerations that will determine how to best promote access to these transformative therapies.
Join us to learn more about this exciting new technology, which has the potential to impact the lives of patients living with genetic disorders profoundly.
- 12:00 PM Welcome Remarks: John Newby, CEO, VA Bio & Delegate Michelle Maldonado
- 12:10 PM Gene Therapy Technology: Andrew Krouse, CEO, Slate Bio
- 12:20 PM Patient Perspective: Colin Werth, Parent Project Muscular Dystrophy
- 12:30 PM Ensuring Patient Access and System Sustainability: Mark Trusheim, MIT
- 12:50 PM Q&A
- 1:00 PM Closing Remarks /Adjourn – Patrick Plues, VP, State Government Affairs, BIO & John Newby